GlassScriptPhysician profile
Stephanie Lanoue
NPI 1457994816
$4,058.51
in general payments reported to CMS, 2019-2025
17 companies · $2,787 in 2025
The $2,787 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $153 · 2023: $177 · 2024: $942 · 2025: $2,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Travel and Lodging: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.39 |
| Travel and Lodging | $1,226.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $2,123.85 | 2024-2025 | Barostim Neo System |
| Biotronik INC. | $430.62 | 2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| Janssen Pharmaceuticals, INC | $299.13 | 2024 | Xarelto |
| Heartflow, INC. | $194.85 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.02 | 2022-2023 | Lifevest |
| Scpharmaceuticals INC. | $138.67 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $126.48 | 2023-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.03 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $122.92 | 2024-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $83.07 | 2022-2025 | Wainua |
| Boston Scientific Corporation | $58.41 | 2025 | Accolade Sr |
| Amgen INC. | $55.17 | 2023-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $47.68 | 2023 | |
| Novo Nordisk INC | $40.25 | 2024 | Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $26.74 | 2025 | Uptravi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.75 | 2025 | |
| Glaxosmithkline, LLC. | $15.87 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lanoue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.